This echoes one of the recent findings that EGFR‐TKI‐resistant SCLCs can branch out from early events that pre‐existed in NSCLC prior to transformation based on tumour biopsy analysis (Lee et al, 2017). This evidence concerns the gene EGFR and non-small cell lung carcinoma.